Cargando…

Clinical Role of Aspirin in Mood Disorders: A Systematic Review

Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Qin Xiang, Ramamoorthy, Krishnapriya, Loke, Wayren, Lee, Matthew Wei Liang, Yeo, Wee Song, Lim, Donovan Yutong, Sivalingam, Vivekanandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895819/
https://www.ncbi.nlm.nih.gov/pubmed/31671812
http://dx.doi.org/10.3390/brainsci9110296
_version_ 1783476639031623680
author Ng, Qin Xiang
Ramamoorthy, Krishnapriya
Loke, Wayren
Lee, Matthew Wei Liang
Yeo, Wee Song
Lim, Donovan Yutong
Sivalingam, Vivekanandan
author_facet Ng, Qin Xiang
Ramamoorthy, Krishnapriya
Loke, Wayren
Lee, Matthew Wei Liang
Yeo, Wee Song
Lim, Donovan Yutong
Sivalingam, Vivekanandan
author_sort Ng, Qin Xiang
collection PubMed
description Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional impairments. Aspirin, a common nonsteroidal anti-inflammatory drug (NSAID), has purported beneficial effects on mood symptoms, showing protective effects against depression in early cohort studies. This systematic review thus aimed to investigate the role of aspirin in mood disorders. Using the keywords (aspirin or acetylsalicy* or asa) and (mood or depress* or bipolar or mania or suicid*), a comprehensive search of PubMed, EMBASE, Medline, PsycINFO, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases found 13,952 papers published in English between 1 January 1988 and 1 May 2019. A total of six clinical studies were reviewed. There were two randomized, placebo-controlled, double-blind trials and populations drawn from two main cohort studies (i.e., the Geelong Osteoporosis Study and the Osteoarthritis Initiative study). Using a random-effects model, the pooled hazard ratio of the three cohort studies was 0.624 (95% confidence interval: 0.0503 to 1.198, p = 0.033), supporting a reduced risk of depression with aspirin exposure. Overall, the dropout rates were low, and aspirin appears to be well-tolerated with minimal risk of affective switch. In terms of methodological quality, most studies had a generally low risk of bias. Low-dose aspirin (80 to 100 mg/day) is safe, well-tolerated and potentially efficacious for improving depressive symptoms in both unipolar and bipolar depression. Due to its ability to modulate neuroinflammation and central nervous system processes, aspirin may also have valuable neuroprotective and pro-cognitive effects that deserve further exploration. Further randomized, controlled trials involving the adjunctive use of aspirin should be encouraged to confirm its therapeutic benefits.
format Online
Article
Text
id pubmed-6895819
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68958192019-12-24 Clinical Role of Aspirin in Mood Disorders: A Systematic Review Ng, Qin Xiang Ramamoorthy, Krishnapriya Loke, Wayren Lee, Matthew Wei Liang Yeo, Wee Song Lim, Donovan Yutong Sivalingam, Vivekanandan Brain Sci Article Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional impairments. Aspirin, a common nonsteroidal anti-inflammatory drug (NSAID), has purported beneficial effects on mood symptoms, showing protective effects against depression in early cohort studies. This systematic review thus aimed to investigate the role of aspirin in mood disorders. Using the keywords (aspirin or acetylsalicy* or asa) and (mood or depress* or bipolar or mania or suicid*), a comprehensive search of PubMed, EMBASE, Medline, PsycINFO, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases found 13,952 papers published in English between 1 January 1988 and 1 May 2019. A total of six clinical studies were reviewed. There were two randomized, placebo-controlled, double-blind trials and populations drawn from two main cohort studies (i.e., the Geelong Osteoporosis Study and the Osteoarthritis Initiative study). Using a random-effects model, the pooled hazard ratio of the three cohort studies was 0.624 (95% confidence interval: 0.0503 to 1.198, p = 0.033), supporting a reduced risk of depression with aspirin exposure. Overall, the dropout rates were low, and aspirin appears to be well-tolerated with minimal risk of affective switch. In terms of methodological quality, most studies had a generally low risk of bias. Low-dose aspirin (80 to 100 mg/day) is safe, well-tolerated and potentially efficacious for improving depressive symptoms in both unipolar and bipolar depression. Due to its ability to modulate neuroinflammation and central nervous system processes, aspirin may also have valuable neuroprotective and pro-cognitive effects that deserve further exploration. Further randomized, controlled trials involving the adjunctive use of aspirin should be encouraged to confirm its therapeutic benefits. MDPI 2019-10-29 /pmc/articles/PMC6895819/ /pubmed/31671812 http://dx.doi.org/10.3390/brainsci9110296 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ng, Qin Xiang
Ramamoorthy, Krishnapriya
Loke, Wayren
Lee, Matthew Wei Liang
Yeo, Wee Song
Lim, Donovan Yutong
Sivalingam, Vivekanandan
Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title_full Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title_fullStr Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title_full_unstemmed Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title_short Clinical Role of Aspirin in Mood Disorders: A Systematic Review
title_sort clinical role of aspirin in mood disorders: a systematic review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895819/
https://www.ncbi.nlm.nih.gov/pubmed/31671812
http://dx.doi.org/10.3390/brainsci9110296
work_keys_str_mv AT ngqinxiang clinicalroleofaspirininmooddisordersasystematicreview
AT ramamoorthykrishnapriya clinicalroleofaspirininmooddisordersasystematicreview
AT lokewayren clinicalroleofaspirininmooddisordersasystematicreview
AT leematthewweiliang clinicalroleofaspirininmooddisordersasystematicreview
AT yeoweesong clinicalroleofaspirininmooddisordersasystematicreview
AT limdonovanyutong clinicalroleofaspirininmooddisordersasystematicreview
AT sivalingamvivekanandan clinicalroleofaspirininmooddisordersasystematicreview